Dr. Ram Palanki currently serves as executive vice president of commercial strategy & operations at REGENXBIO, a leader in AAV gene therapy, and is responsible for the planning, execution and commercialization of their pipeline across the ophthalmology, central nervous system and neuromuscular disease franchises.

He has nearly 20 years of drug development and commercialization experience in the biopharmaceutical and device industry. Before joining REGENXBIO, he was senior vice president of Commercial for all of Americas at Santen Inc. Previously, he served as the executive team member and lead the global marketing, sales, pricing, reimbursement, commercial operations and alliance management functions at ThromboGenics.

Over the span of his career, Dr. Palanki has held roles of increasing responsibility at several small, mid and large companies, including NeoVista Inc, and Genentech.  He actively serves as a board member and strategic advisor to multiple biotech, technology start-up companies and global non-profits in ophthalmology.